Table 2 Ongoing clinical trials of anti-TIGIT agents
From: Targeting TIGIT for cancer immunotherapy: recent advances and future directions
Cancer types | Name (manufacturer) | Description | Phases | Conditions | NCT Number |
|---|---|---|---|---|---|
Solid tumors | Domvanalimab (Arcus Biosciences) | IgG1 monoclonal antibody | Early Phase 1 | Glioblastoma | NCT04656535 |
| Â | Phase 2 | NSCLC | NCT04262856 | ||
NCT04791839 | |||||
NCT05676931 | |||||
Upper Gastrointestinal Tract Malignancies | NCT05329766 | ||||
Melanoma | NCT05130177 | ||||
Phase 3 | NSCLC | NCT04736173 | |||
NCT05502237 | |||||
NCT05211895 | |||||
Advanced Upper Gastrointestinal Tract Malignancies | NCT05568095 | ||||
| Â | Ociperlimab (BeiGene) | IgG1 monoclonal antibody | Phase 1 | Solid Tumors | NCT04047862 |
Phase 2 | Biliary Tract Carcinoma | NCT05023109 | |||
ESCC | NCT04732494 | ||||
NSCLC | NCT05014815 | ||||
TNBC | NCT05809895 | ||||
Phase 3 | NSCLC | NCT04746924 | |||
NCT04866017 | |||||
| Â | Vibostolimab (Merck) | IgG1 monoclonal antibody | Phase 1 | Advanced Solid Tumors | NCT02964013 |
| Â | Â | Â | Phase 1/2 | Melanoma | NCT04305041 |
NCT04303169 | |||||
NCT04305054 | |||||
Prostate Cancer | NCT02861573 | ||||
Renal Cell Carcinoma | NCT04626479 | ||||
Phase 2 | Solid Tumors | NCT05007106 | |||
NSCLC | NCT04165070 | ||||
Colorectal Cancer | NCT04895722 | ||||
Phase 3 | Lung Cancer | NCT04738487 | |||
NCT05298423 | |||||
NCT05226598 | |||||
SCLC | NCT05224141 | ||||
Melanoma | NCT05665595 | ||||
| Â | Tiragolumab (Roche) | IgG1 monoclonal antibody | Phase 1 | Colorectal Cancer | NCT04929223 |
Urothelial Carcinoma | NCT05394337 | ||||
Phase 1/2 | SMARCB1 or SMARCA4 deficient tumors | NCT05286801 | |||
Melanoma | NCT05116202 | ||||
SCCHN | NCT05459129 | ||||
Urothelial Cancer | NCT03869190 | ||||
GA or GEJ or EC | NCT03281369 | ||||
Liver Cancer | NCT04524871 | ||||
PDAC | NCT03193190 | ||||
Endometrial Cancer | NCT04486352 | ||||
Locally Advanced ESCC | NCT05743504 | ||||
Phase 2 | SCCHN | NCT03708224 | |||
Rectal Cancer | NCT05009069 | ||||
Melanoma | NCT03554083 | ||||
NSCLC or Solid tumors | NCT03977467 | ||||
Non-Squamous NSCLC | NCT04958811 | ||||
NSCLC | NCT04832854 | ||||
Solid Tumors | NCT05483400 | ||||
Renal Cell Carcinoma | NCT05805501 | ||||
Phase 2 | Solid Tumors | NCT05661578 | |||
Squamous Cell Carcinoma of the Anal Canal | NCT05661188 | ||||
Phase 2/3 | Non-Squamous NSCLC | NCT04619797 | |||
Phase 3 | NSCLC | NCT04294810 | |||
NCT04513925 | |||||
ESCC | NCT04543617 | ||||
| Â | Etigilimab (Mereo BioPharma) | IgG1 monoclonal antibody | Phase 1b/2 | Solid Tumors | NCT04761198 |
Phase 2 | Ovarian Cancer | NCT05715216 | |||
| Â | EOS-448 (iTeos Belgium SA) | IgG1 monoclonal antibody | Phase 1 | Solid Tumors | NCT04446351 |
Phase 1/2 | Solid Tumors | NCT05060432 | |||
Phase 2 | NSCLC | NCT03739710 | |||
| Â | HLX301 (Henlius Biotech) | IgG1 Anti-PDL1 and Anti-TIGIT Bispecific Antibody | Phase 1/2 | Solid Tumors | NCT05102214 |
| Â | M6223 (Merck) | IgG1 monoclonal antibody | Phase 1 | Solid Tumors | NCT04457778 |
Phase 2 | Urothelial Cancer | NCT05327530 | |||
| Â | JS006 or CHS-006 (Junshi Bioscience, Coherus Biosciences) | IgG4 monoclonal antibody | Phase 1/2 | Advanced Solid Tumors | NCT05757492 |
| Â | ASP8374 (Astellas Pharma) | IgG4 monoclonal antibody | Phase 1 | Glioblastoma | NCT04826393 |
| Â | BMS-986207 (Bristol-Myers) | IgG1 monoclonal antibody | Phase 1/2 | Solid Tumors | NCT04570839 |
Solid Tumors | NCT02913313 | ||||
| Â | AZD2936 (AstraZeneca) | IgG1 Anti-PD1 and Anti-TIGIT Bispecific Antibody | Phase 1/2 | NSCLC | NCT04995523 |
Phase 2 | Gastric or GEJ Adenocarcinoma | NCT05702229 | |||
| Â | HB0036 (Huaota Biopharm) | Anti-PDL1 and Anti-TIGIT Bispecific Antibody | Phase 1/2 | Solid Tumors | NCT05417321 |
| Â | HB0030 (Huaota Biopharm) | IgG1 monoclonal antibody | Phase 1 | Advanced Solid Tumor | NCT05706207 |
| Â | SEA-TGT (Seagen) | IgG1 monoclonal antibody | Phase 1/2 | NSCLC | NCT04585815 |
| Â | BAT-6005 (Bio-Thera) | IgG1 monoclonal antibody | Phase 1 | Advanced Solid Tumors | NCT05116709 |
| Â | PM1021 (Biotheus) | IgG1 monoclonal antibody | Phase 1 | Advanced Solid Tumors | NCT05537051 |
Hematological tumors | Ociperlimab (BeiGene) | IgG1 monoclonal antibody | Phase 1/2 | DLBCL | NCT05267054 |
Vibostolimab (Merck) | IgG1 monoclonal antibody | Phase 2 | Hematological Malignancies | NCT05005442 | |
Tiragolumab (Roche) | IgG1 monoclonal antibody | Phase 1/2 | BCNHL | NCT05315713 | |
EOS-448 (iTeos Belgium SA) | IgG1 monoclonal antibody | Phase 1/2 | MM | NCT05289492 | |
| Â | BMS-986207 (Bristol-Myers) | IgG1 monoclonal antibody | Phase 1/2 | MM | NCT04150965 |
Combination | Tiragolumab (Roche) | IgG1 monoclonal antibody | Phase 1 | Advanced/Metastatic Tumors | NCT02794571 |
| Â | HLX301 (Henlius Biotech) | IgG1 Anti-PDL1 and Anti-TIGIT Bispecific Antibody | Phase 1/2 | Solid Tumors or Lymphoma | NCT05390528 |
| Â | HLX53 (Henlius Biotech) | IgG1 monoclonal antibody | Phase 1 | Advanced/Metastatic Solid Tumors or Lymphoma | NCT05394168 |
| Â | JS006 or CHS-006 (Junshi Bioscience, Coherus Biosciences) | IgG4 monoclonal antibody | Phase 1 | Advanced tumors | NCT05061628 |
| Â | SEA-TGT (Seagen) | IgG1 monoclonal antibody | Phase 1 | Advanced Cancer | NCT04254107 |
| Â | COM-902 (Compugen) | IgG4 monoclonal antibody | Phase 1 | Advanced Tumors | NCT04354246 |
| Â | AB308 (Arcus Biosciences) | IgG1 monoclonal antibody | Phase 1 | Advanced Tumors | NCT04772989 |
| Â | PM1009 (Biotheus) | IgG1 Anti-TIGIT and Anti- PVRIG Bispecific Antibody | Phase 1 | Advanced Tumors | NCT05607563 |
|  | AK130 (Akeso) | Anti-TIGIT and Anti-TGF-β Bispecific Antibody | Phase 1 | Advanced Malignant Tumors | NCT05653284 |